187 related articles for article (PubMed ID: 25621798)
61. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
62. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
63. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
64. Impact of very early CD4(+) /CD8(+) T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation.
Huttunen P; Taskinen M; Siitonen S; Saarinen-Pihkala UM
Pediatr Blood Cancer; 2015 Mar; 62(3):522-8. PubMed ID: 25417898
[TBL] [Abstract][Full Text] [Related]
65. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study.
Martino R; Giralt S; Caballero MD; Mackinnon S; Corradini P; Fernández-Avilés F; San Miguel J; Sierra J
Haematologica; 2003 May; 88(5):555-60. PubMed ID: 12745275
[TBL] [Abstract][Full Text] [Related]
66. Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates.
Zhang XH; Xu LP; Liu DH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Wang Y; Zhao T; Chen Y; Fu HX; Liu KY; Huang XJ
Clin Transplant; 2013; 27(1):80-9. PubMed ID: 22938074
[TBL] [Abstract][Full Text] [Related]
67. Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties.
Greco R; Labopin M; Badoglio M; Veys P; Furtado Silva JM; Abinun M; Gualandi F; Bornhauser M; Ciceri F; Saccardi R; Lankester A; Alexander T; Gennery AR; Bader P; Farge D; Snowden JA
Front Immunol; 2019; 10():1570. PubMed ID: 31333680
[No Abstract] [Full Text] [Related]
68. Hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia and Down syndrome.
Goto H; Kaneko T; Shioda Y; Kajiwara M; Sakashita K; Kitoh T; Hayakawa A; Miki M; Kato K; Ogawa A; Hashii Y; Inukai T; Kato C; Sakamaki H; Yabe H; Suzuki R; Kato K
Pediatr Blood Cancer; 2015 Jan; 62(1):148-52. PubMed ID: 25262825
[TBL] [Abstract][Full Text] [Related]
69. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
Chen YB; Li S; Fisher DC; Driscoll J; Del Rio C; Abramson J; Armand P; Barnes J; Brown J; Cutler C; El-Jawahri A; Ho VT; Hochberg E; McAfee S; Takvorian R; Spitzer TR; Antin JH; Soiffer R; Jacobsen E
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1583-8. PubMed ID: 26009261
[TBL] [Abstract][Full Text] [Related]
70. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
71. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
72. Adverse health events and late mortality after pediatric allogeneic hematopoietic SCT-two decades of longitudinal follow-up.
Wilhelmsson M; Vatanen A; Borgström B; Gustafsson B; Taskinen M; Saarinen-Pihkala UM; Winiarski J; Jahnukainen K
Bone Marrow Transplant; 2015 Jun; 50(6):850-7. PubMed ID: 25798676
[TBL] [Abstract][Full Text] [Related]
73. Clinical-associated characteristics and microbiological features of bloodstream nontyphoidal salmonella infection in adult patients receiving allogeneic hematopoietic stem cell transplantation.
Ko PS; Liu YC; Wang HY; Wu CY; Fan NW; Liu CJ; Yu YB; Hsiao LT; Chiou TJ; Tzeng CH; Liu JH; Gau JP
Ann Hematol; 2017 Sep; 96(9):1533-1540. PubMed ID: 28710648
[TBL] [Abstract][Full Text] [Related]
74. Asymmetric dimethylarginine serum levels are associated with early mortality after allogeneic stem cell transplantation.
Radujkovic A; Dai H; Kordelas L; Beelen D; Rachakonda SP; Müller-Tidow C; Kumar R; Dreger P; Luft T
Haematologica; 2019 Apr; 104(4):827-834. PubMed ID: 30514796
[TBL] [Abstract][Full Text] [Related]
75. Why is a 3-year NRM following allogeneic transplantation still stuck at approximately 20%?
Barrett J
Best Pract Res Clin Haematol; 2018 Dec; 31(4):414-419. PubMed ID: 30466759
[TBL] [Abstract][Full Text] [Related]
76. Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant.
Ngo-Huang A; Ombres R; Saliba RM; Szewczyk N; Adekoya L; Soones TN; Ferguson J; Fontillas RC; Gulbis AM; Hosing C; Kebriaei P; Lindsay R; Marin DC; Mehta RS; Alousi AM; Srour S; Oran B; Olson AL; Qazilbash MH; Rivera Z; Champlin RE; Shpall EJ; Popat UR
JCO Oncol Pract; 2023 Mar; 19(3):e417-e427. PubMed ID: 36626702
[TBL] [Abstract][Full Text] [Related]
77. Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation.
Dandoy CE; Haslam D; Lane A; Jodele S; Demmel K; El-Bietar J; Flesch L; Myers KC; Pate A; Rotz S; Daniels P; Wallace G; Nelson A; Waters H; Connelly B; Davies SM
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1671-1677. PubMed ID: 27311966
[TBL] [Abstract][Full Text] [Related]
78. The use of low doses of methotrexate during peri-cell infusion period may be a risk factor for acute kidney injury in patients subjected to hematopoietic stem cell transplantation.
Ferraz FTP; Marra AR; Hamerschlak N; de Souza Durão Junior M
Ann Hematol; 2020 Mar; 99(3):627-633. PubMed ID: 31965273
[TBL] [Abstract][Full Text] [Related]
79. Immunoglobulin prophylaxis in pediatric hematopoietic stem cell transplant.
Foster JH; Cheng WS; Nguyen NY; Krance R; Martinez C
Pediatr Blood Cancer; 2018 Dec; 65(12):e27348. PubMed ID: 30207052
[TBL] [Abstract][Full Text] [Related]
80. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease.
García-Cadenas I; Rivera I; Martino R; Esquirol A; Barba P; Novelli S; Orti G; Briones J; Brunet S; Valcarcel D; Sierra J
Bone Marrow Transplant; 2017 Jan; 52(1):107-113. PubMed ID: 27595281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
